# A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

> **NCT04457336** · PHASE2 · TERMINATED · sponsor: **Spruce Biosciences** · enrollment: 96 (actual)

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** Tildacerfont/Placebo

## Key facts

- **NCT ID:** NCT04457336
- **Lead sponsor:** Spruce Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-26
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-05-23
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** Study SPR001-203 did not meet its primary and secondary endpoints therefore Spruce Biosciences has decided to terminate the study
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457336, "A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04457336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*